Diagnostic accuracy and safety of percutaneous core needle biopsy of retroperitoneal tumours.
Walter Nardi, Nayla Nicolas, Sophie El Zein...
https://pubmed.ncbi.nlm.nih.gov/38086314/Actively Recruiting
Led by European Organisation for Research and Treatment of Cancer - EORTC · Updated on 2026-10-07
250
Participants Needed
176
Research Sites
52 weeks
Total Duration
Researchers are investigating whether adding preoperative chemotherapy to surgery improves the outcomes for patients with high risk retroperitoneal sarcoma, specifically dedifferentiated liposarcoma DDLPS and leiomyosarcoma LMS. This phase III randomized trial compares the effects of surgery alone versus surgery following chemotherapy on disease-free survival in these patients. Participants are assigned to one of two groups the standard treatment group, which undergoes large en-bloc curative-intent surgery within four weeks after randomization, or the experimental group, which receives three cycles of chemotherapy before surgery. Chemotherapy regimens differ by sarcoma type, with high grade LPS patients receiving doxorubicin plus ifosfamide every three weeks, and LMS patients receiving doxorubicin plus dacarbazine every three weeks. Surgery is then scheduled 3 to 6 weeks after the last chemotherapy cycle, with doses adapted per institutional guidelines. During the study, participants undergo imaging assessments to evaluate tumor operability and response to treatment. Researchers monitor disease-free survival over seven years from the first patient enrolled, along with secondary outcomes including overall survival, recurrence, metastasis rates, treatment safety, quality of life, and pathological response. Participants are closely followed through scheduled visits and tests to assess treatment effects and potential complications until study completion in 2028.
CONDITIONS
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
E
EORTC HQ
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
European Organisation for Research and Treatment of Cancer - EORTC
Lead Sponsor
Canadian Cancer Trials Group
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Preoperative chemotherapy + surgery | Surgery alone | Standard treatment (surgery) |
|---|---|---|---|
| What it is | A randomized trial arm combining preoperative chemotherapy followed by large en‑bloc curative‑intent surgery. | A randomized trial arm involving surgery alone with large en‑bloc curative‑intent resection. | Complete surgical resection alone remains the accepted standard of care for localized resectable retroperitoneal sarcoma. |
| Role in trial | Investigational arm being evaluated for added benefit of preoperative chemotherapy. | Control arm reflecting current practice of surgery without preoperative chemotherapy. | Reflects the standard treatment outside the trial setting. |
| Primary use | Intended to improve outcomes by using chemotherapy before surgery. | Standard removal of tumor by surgery alone. | Complete surgical resection without chemotherapy. |
| How it is given or performed | Three cycles of histology‑driven chemotherapy followed by en‑bloc surgery. | Immediate large en‑bloc curative‑intent surgery without prior chemotherapy. | En‑bloc surgical resection alone. |
| Evidence status | Effectiveness of adding neoadjuvant chemotherapy is not yet established; randomized data from this trial are pending. | Long-standing effectiveness of surgery for localized resectable retroperitoneal sarcoma but limited long‑term survival. | Surgery alone is standard of care; neoadjuvant chemotherapy remains experimental. |
| Important risks | Potential chemotherapy‑related toxicities plus surgical risks, not yet fully characterized in this setting. | Surgical risks such as bleeding, infection, organ injury, but no chemotherapy‑related toxicity. | Risks are limited to surgical complications with no added systemic toxicity. |
| Important limitations | Effect of preoperative chemotherapy uncertain and randomized results are not yet available. | Long‑term survival remains poor with surgery alone, and relapse rates are high. | Although standard, surgery alone does not address systemic relapse risk; adjunctive strategies have uncertain benefit. |
| Patient impact | Not yet known; impact on survival and quality of life will depend on trial outcomes. | Established surgical approach but long‑term outcomes remain modest. | Standard treatment though relapse risks remain; alternative strategies are experimental. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 9 to 12 weeks
Participants receive either surgery alone or three cycles of preoperative chemotherapy followed by surgery. Chemotherapy doses are adjusted per guidelines based on sarcoma type, followed by surgery to remove the tumor.
Multiple visits during chemotherapy and pre-surgical assessments
Duration - Up to 7 years
Participants are monitored for disease-free survival and other outcomes through regular visits and assessments over several years after treatment completion.
Regular scheduled follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Walter Nardi, Nayla Nicolas, Sophie El Zein...
https://pubmed.ncbi.nlm.nih.gov/38086314/European Organisation for Research and Treatment of Cancer - EORTC
Lead Sponsor
Canadian Cancer Trials Group
Collaborating Sponsor